• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,859.73
  • 0.16 %
  • $65.13
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,160.27
  • -0.29 %
  • -$23.97
  • IXIC
  • $18,312.83
  • 0.73 %
  • $132.85
Mereo BioPharma Group plc (MREO) Stock Price, News & Analysis

Mereo BioPharma Group plc (MREO) Stock Price, News & Analysis

Currency in USD Disclaimer

$4.00

-$0.01

(-0.2%)

Day's range
$4
Day's range
$4
50-day range
$3.88
Day's range
$4.95
  • Country: GB
  • ISIN: US5894921072
52 wk range
$1.86
Day's range
$5.02
  • CEO: Dr. Denise Vera Scots-Knight Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 15.43
  • Piotroski Score 4.00
  • Grade Overweight
  • Symbol (MREO)
  • Company Mereo BioPharma Group plc
  • Price $4.00
  • Changes Percentage (-0.2%)
  • Change -$0.01
  • Day Low $4.00
  • Day High $4.00
  • Year High $5.02

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/27/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $7.50
  • High Stock Price Target $8.00
  • Low Stock Price Target $4.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.15
  • Trailing P/E Ratio -22.8
  • Forward P/E Ratio -22.8
  • P/E Growth -22.8
  • Net Income $-29,466,000

Income Statement

Quarterly

Annual

Latest News of MREO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.